Astellas Responds To "Approvable" Letter For Prograf MR Kidney Transplant Claim
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma has responded to an FDA "approvable" letter for use of the once-daily immunosuppressant Prograf MR (tacrolimus modified-release) to prevent rejection of kidney transplants, the Japanese firm announced Sept. 19